| President | |
| Wolf Consulting Services | |
| August 2010 - Present (13 years 1 month) |
| Manager | |
| American Express | |
| 2000 - 2010 (10 years 7 months) |
| Investors Alley | |
| Bret Jensen | |
|
Investors Alley is an investment research publisher providing unbiased actionable investing and trading advice to individual investors. I serve as the lead analyst for small cap and turnaround stocks and serve as the editor for newsletters covering both. Newsletter issues contain independent, vetted investment research in the small cap and turnaround space including deep dives into individual stock opportunities, updates on current portfolio holdings, and performance tracking and commentary. |
| Small Cap Gems - $99 Annually | |
| Bret Jensen | |
| Investors Alley | |
|
The focus of the letter is to give you high quality research on small cap stocks poised for double and triple digit growth. This can sound a little over the top… I get all the ads from other newsletters, too. But there’s a fundamental difference between those letters and mine: I buy the stocks I recommend. |
| Turnaround Stock Report - $499 Annually | |
| Bret Jensen | |
| Investors Alley | |
|
The focus of The Turnaround Stock Report is to recommend stocks that provide opportunities for relatively fast, attractive profits around stocks that have been oversold on the news, beaten down by flighty investors, had management shaken up and the whole company turned around. Each issue of The Turnaround Stock Report is filled with recovering stocks, “busted” initial public offerings, companies where activist investors have shaken up management and moved the company forward. These are the companies that most investors are too scared to touch. They see the past as being an indicator of future performance. And while that may hold true for many stocks, these are different. These are companies we zero in on for huge profits. |
Latest Comments
2 Hot Biotechs Set To Deliver Paydays To Investors In 2015
Sold AVNR at buyout price of $17. Still hold the rocket know as ZIOP but have sold some $10 calls against part of position given lucrative premium and huge run. Still hold SGYP
2 Hot Biotechs Set To Deliver Paydays To Investors In 2015
I believe you posted this question and I answered on seekingalpha, correct me if I am wrong. Thanks for following and Happy Hunting.
2 Hot Biotechs Set To Deliver Paydays To Investors In 2015
Depends on your risk tolerance, certainly not a bad way to go. I usually have 50% to 75% of biotech/biopharma in three or four large caps with visible earnings growth. The rest is in 12 to 15 much more speculative small caps looking for the home runs (AVNR, NVAX, LCI,TTPH, ZLTQ) that I have nailed over the past couple of years....which balances out the frequent strike outs that are a part of investing in this volatile space. Happy Hunting.
2 Hot Biotechs Set To Deliver Paydays To Investors In 2015
Thanks. It is an interesting stock that is starting to get some notice.
3 Cult Stocks To Avoid In 2015
Thanks. GILD one of the cheapest large cap growth plays in the market right now....
2 Triple Digit Winners For Under $2
Have it on my "to do" list. Getting device in channels for reimbursement is going to be company's main task over next year.
Conatus Pharmaceutical: Act II In Fighting Liver Disease
Always good to spread your bets across this very volatile sector. That is why I place many more tiny bets across myriad names in small cap biotech plays. I have dubbed this "ShotGun Investing" in many pieces on SeekingAlpha and Real Money Pro. Also why my monthly newsletter Small Cap Gems (smallcapgems.com) has several names including have been very fortunate to have AVNR as one of inaugural picks in July. Great run before being bought out this month. Have looked at LJPC before but will take another look. Thanks for the comment. Happy Hunting.
Bret